

# G.D. Apte & Co. Chartered Accountants

## Limited Review Report

### The Board of Directors Take Solutions Limited

1. We were engaged to review the accompanying Statement of unaudited consolidated financial results of Take Solutions Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The Statement is the responsibility of the Parent's Management and is approved by its Board of Directors. The Statement is required to be prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. Because of the matters described in paragraph 5 below, we were not able to obtain sufficient appropriate evidence to provide a basis for conclusion and hence we do not express a conclusion on the Statement.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143 (10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the consolidation of results pertaining to the entities listed in Annexure.

### 5. Basis for Disclaimer of Conclusion

We draw attention to the below mentioned matters pertaining to various elements of the statement that may require necessary adjustments/ disclosures in the statement and these adjustments when made may have material and pervasive impact on the outcome of the statement for the quarter and nine months ended December 31, 2021:

- a. We are unable to evaluate adequacy of expected credit losses as required under 'IND AS 109 Financial Instruments' in respect of trade receivables of Rs. 383 Crores, unbilled receivables of Rs. 57 Crores, other financial/other current assets of Rs. 323 Crores since the same are

---

Pune Office: GDA House, Plot No.85, Right Bhusari Colony, Paud Road, Kothrud, Pune – 411 038, Phone – 020 – 66807200,  
Email – [audit@gdaca.com](mailto:audit@gdaca.com)

Mumbai Office: Windsor, 6<sup>th</sup> Floor, OfficeNo-604, C.S.T. Road, Kalina, Santacruz (East), Mumbai-400 098



**G.D. Apte & Co.**  
Chartered Accountants

subject to scrutiny and internal review by the company, confirmations, reconciliation and consequential adjustments, if any.

- b. The lender banks have cancelled and recalled the credit facilities of Rs. 452 Crores (approx) for a group company viz. TAKE Solutions Global Holdings Pte Ltd, Singapore (TAKE Ghpte) and have initiated disposal of equity share investments held by the parent company to recover their dues out of the sale proceeds. The parent company had entered into agreements for sale of shares in group companies to H.I.G. Taurus Pte. Ltd. and H.I.G. Taurus EAL Pte. Ltd. and to repay the credit facilities to the lender banks of TAKE Ghpte. In our view, the future repayments to the lender banks are uncertain since the then proposed sale has been suspended in view of order from High Court of Madras.
- c. The group should have carried out the impairment testing of goodwill and other intangible assets aggregating to Rs. 678 Crores as required by 'IND AS 36 Impairment of Assets' in view of above paras and we are unable to obtain sufficient appropriate evidence in support of the contention of management that there is no indication of any impairment.

The overall impact of the above on the statement cannot be ascertained.

**6. Disclaimer of Conclusion**


In view of the significance of the matters described in aforesaid paragraphs narrating our 'Basis for Disclaimer of Conclusion', we have not been able to obtain sufficient and appropriate evidence as to whether the statement has been prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian accounting Standards and other accounting principles generally accepted in India or state whether the statement has disclosed the information required to be disclosed in terms of SEBI regulations 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.

For G. D. Apte & Co.

Chartered Accountants

Firm Registration Number: 100 515W

UDIN: 22113053AAXAMS1050



Umesh S. Abhyankar

Partner

Membership Number: 113053

Pune, February 8, 2022



---

**Pune Office:** GDA House, Plot No.85, Right Bhusari Colony, Paud Road, Kothrud, Pune – 411 038, Phone – 020 – 66807200,  
Email – [audit@gdaca.com](mailto:audit@gdaca.com)

**Mumbai Office:** Windsor, 6<sup>th</sup> Floor, OfficeNo-604, C.S.T. Road, Kalina, Santacruz (East), Mumbai-400 098

**G.D. Apte & Co.**  
Chartered Accountants

**Annexure**

Annexure referred to in Paragraph 4 of our Limited Review Report on the Consolidated Financial Results of TAKE Solutions Limited for the quarter and nine months ended December 31, 2021

| Sr. No. | Particulars   |
|---------|---|
| A       | <b>Subsidiaries</b>   |
| 1       | Ecron Acunova Limited   |
| 2       | TAKE Solutions Global Holding Pte Ltd   |
| 3       | TAKE Solutions Limited ESOP Trust   |
| 4       | Navitas LLP   |
| B       | <b>Step Down Subsidiaries</b>   |
| 1       | NLS Holdings SG Pte Ltd, Singapore<br>(Formerly known as TAKE Solutions Information Systems Pte Ltd, Singapore) |
| 2       | TAKE Enterprise Services Inc., USA  |
| 3       | TAKE Innovations Inc , USA  |
| 4       | Navitas Life Sciences Holdings Limited, UK  |
| 5       | Intelent Inc, USA   |
| 6       | Navitas Life Sciences Limited, UK   |
| 7       | Navitas Life Sciences LLC, Russia   |
| 8       | Navitas Inc., USA   |
| 9       | Navitas Life Sciences S. A. S. Colombia   |
| 10      | Navitas Life Sciences SG Pte. Limited   |
| 11      | Navitas Life Sciences Services Limited, UK  |
| 12      | Navitas Life Sciences Services Inc, USA   |
| 13      | Acunova Life Science Inc., USA  |
| 14      | Navitas Life sciences Company Limited, Thailand   |
| 15      | Acunova Life Sciences Limited, UK   |

Pune Office: GDA House, Plot No.85, Right Bhusari Colony, Paud Road, Kothrud, Pune – 411 038, Phone – 020 – 66807200,  
Email – [audit@gdaca.com](mailto:audit@gdaca.com)

Mumbai Office: Windsor, 6<sup>th</sup> Floor, OfficeNo-604, C.S.T. Road, Kalina, Santacruz (East), Mumbai-400 098





TAKE SOLUTIONS LTD


CIN: L63090TN2000PLC046338

Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034  
www.takesolutions.com

## Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021

(₹ In Lakhs except per share data)

| Sl.<br>No. | Particulars   | Quarter Ended     |                  |                   | Nine Months ended |                    | Year Ended         |
|------------|---|-------------------|------------------|-------------------|-------------------|--------------------|--------------------|
|            |   | Dec 31,<br>2021   | Sep 30,<br>2021  | Dec 31,<br>2020   | Dec 31,<br>2021   | Dec 31,<br>2020    | Mar 31,<br>2021    |
|            |   | (Unaudited)       | (Unaudited)      | (Unaudited)       | (Unaudited)       | (Unaudited)        | (Audited)          |
| <b>A</b>   | <b>CONTINUING OPERATIONS</b>  |                   |                  |                   |                   |                    |                    |
| 1          | Revenue from operations   | 20,739.67         | 19,742.33        | 21,639.15         | 61,397.38         | 55,301.97          | 77,401.45          |
| 2          | Other Income  | 868.23            | 230.03           | 956.52            | 1,349.58          | 1,333.86           | 1,199.66           |
| 3          | <b>Total Revenue</b>  | <b>21,607.90</b>  | <b>19,972.36</b> | <b>22,595.67</b>  | <b>62,746.96</b>  | <b>56,635.83</b>   | <b>78,601.11</b>   |
| 4          | <b>Expenses</b>   |                   |                  |                   |                   |                    |                    |
|            | Cost of revenue   | 6,140.89          | 5,173.64         | 5,374.00          | 17,375.64         | 13,912.79          | 18,807.73          |
|            | Employee benefit expenses   | 9,939.77          | 9,482.40         | 11,908.98         | 28,762.40         | 38,381.34          | 47,375.35          |
|            | Finance cost  | 910.65            | 764.99           | 939.81            | 2,747.25          | 2,903.09           | 3,731.03           |
|            | Depreciation and amortisation   | 2,278.39          | 2,577.53         | 2,831.89          | 7,352.81          | 8,729.73           | 11,538.03          |
|            | Other expenses  | 6,412.36          | 2,695.29         | 3,819.17          | 11,555.71         | 14,760.57          | 18,521.78          |
|            | <b>Total Expenses</b>   | <b>25,682.06</b>  | <b>20,693.85</b> | <b>24,873.85</b>  | <b>67,793.81</b>  | <b>78,687.52</b>   | <b>99,973.92</b>   |
| 5          | <b>Profit/(Loss) before exceptional items and tax (3-4)</b>   | <b>(4,074.16)</b> | <b>(721.49)</b>  | <b>(2,278.18)</b> | <b>(5,046.85)</b> | <b>(22,051.69)</b> | <b>(21,372.81)</b> |
| 6          | Exceptional items   | -                 | -                | -                 | -                 | (15,662.33)        | (22,506.78)        |
| 7          | <b>Profit/(Loss) before tax (5+6)</b>   | <b>(4,074.16)</b> | <b>(721.49)</b>  | <b>(2,278.18)</b> | <b>(5,046.85)</b> | <b>(37,714.02)</b> | <b>(43,879.59)</b> |
| 8          | <b>Tax expense</b>  |                   |                  |                   |                   |                    |                    |
|            | Current tax   | 150.94            | 238.75           | 85.65             | 753.84            | 467.17             | 1,353.98           |
|            | Shortfall / (excess) provision of earlier years   | -                 | -                | -                 | (110.40)          | -                  | (118.44)           |
|            | Deferred tax  | (40.69)           | (76.75)          | 201.13            | (300.96)          | 240.70             | 119.50             |
| 9          | <b>Profit/(Loss) for the period from continuing operations (7-8)</b>  | <b>(4,184.41)</b> | <b>(883.49)</b>  | <b>(2,564.96)</b> | <b>(5,389.33)</b> | <b>(38,421.89)</b> | <b>(45,234.63)</b> |
| <b>B</b>   | <b>DISCONTINUED OPERATIONS</b>  |                   |                  |                   |                   |                    |                    |
| 10         | <b>Profit/(Loss) from discontinued operations before tax</b>  | -                 | -                | 19.26             | -                 | 317.46             | 317.46             |
| 11         | Less: Tax expense on discontinued operations  | -                 | -                | -                 | -                 | 89.96              | 89.96              |
| 12         | <b>Profit/(Loss) for the period from discontinued operations (10-11)</b>                                      | -                 | -                | 19.26             | -                 | 227.50             | 227.50             |
| 13         | <b>Total Profit/(Loss) for the period (9+12)</b>  | <b>(4,184.41)</b> | <b>(883.49)</b>  | <b>(2,545.70)</b> | <b>(5,389.33)</b> | <b>(38,194.39)</b> | <b>(45,007.13)</b> |
| 14         | <b>Profit/(Loss) for the period from continuing operations (9)</b>  |                   |                  |                   |                   |                    |                    |
|            | <b>Attributable to:</b>   |                   |                  |                   |                   |                    |                    |
|            | Shareholders of the company   | (4,181.80)        | (888.91)         | (2,564.70)        | (5,390.15)        | (38,533.67)        | (45,342.56)        |
|            | Non-controlling interest  | (2.61)            | 5.42             | (0.26)            | 0.82              | 111.78             | 107.93             |
|            |   | <b>(4,184.41)</b> | <b>(883.49)</b>  | <b>(2,564.96)</b> | <b>(5,389.33)</b> | <b>(38,421.89)</b> | <b>(45,234.63)</b> |
| 15         | <b>Profit/(Loss) for the period from discontinued operations (12)</b>   |                   |                  |                   |                   |                    |                    |
|            | <b>Attributable to:</b>   |                   |                  |                   |                   |                    |                    |
|            | Shareholders of the company   | -                 | -                | 19.26             | -                 | 140.04             | 140.04             |
|            | Non-controlling interest  | -                 | -                | -                 | -                 | 87.46              | 87.46              |
|            |   | -                 | -                | <b>19.26</b>      | -                 | <b>227.50</b>      | <b>227.50</b>      |
| 16         | <b>Other Comprehensive Income from continuing operations</b>  |                   |                  |                   |                   |                    |                    |
|            | a) i) Items that will not be reclassified to profit or (loss)   | 16.54             | 43.18            | 78.20             | 22.39             | 61.86              | 125.27             |
|            | ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss) | 5.08              | 13.70            | 26.16             | 7.64              | 20.18              | 38.45              |
|            | b) i) Items that will be reclassified to profit or (loss)   | 980.39            | 1,779.44         | (442.46)          | 1,303.46          | (10.06)            | 403.02             |
|            | ii) Income tax provision / (reversal) relating to the items that will be reclassified to profit or (loss)     | 3.94              | 6.43             | (7.43)            | 7.95              | (15.63)            | (4.00)             |
|            | <b>Total Other Comprehensive Income from continuing operations</b>  | <b>987.91</b>     | <b>1,802.49</b>  | <b>(382.99)</b>   | <b>1,310.26</b>   | <b>47.25</b>       | <b>493.84</b>      |
| 17         | <b>Other Comprehensive Income from discontinued operations</b>  |                   |                  |                   |                   |                    |                    |
|            | Items that will not be reclassified to profit or (loss)   | -                 | -                | -                 | -                 | -                  | (5.97)             |
|            | Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)     | -                 | -                | -                 | -                 | -                  | (2.12)             |
|            | <b>Total Other Comprehensive Income from discontinued operations</b>  | -                 | -                | -                 | -                 | -                  | (3.85)             |
| 18         | <b>Total Other Comprehensive Income</b>   | <b>987.91</b>     | <b>1,802.49</b>  | <b>(382.99)</b>   | <b>1,310.26</b>   | <b>47.25</b>       | <b>489.99</b>      |
| 19         | <b>Other Comprehensive Income from continuing operations (16)</b>   |                   |                  |                   |                   |                    |                    |
|            | <b>Attributable to:</b>   |                   |                  |                   |                   |                    |                    |
|            | Shareholders of the company   | 989.64            | 1,813.20         | (379.14)          | 1,321.75          | 56.09              | 497.66             |
|            | Non-controlling interest  | (1.73)            | (10.71)          | (3.85)            | (11.49)           | (8.84)             | (3.82)             |
|            |   | <b>987.91</b>     | <b>1,802.49</b>  | <b>(382.99)</b>   | <b>1,310.26</b>   | <b>47.25</b>       | <b>493.84</b>      |
| 20         | <b>Total Other Comprehensive Income from discontinued operations (17)</b>                                     |                   |                  |                   |                   |                    |                    |
|            | <b>Attributable to:</b>   |                   |                  |                   |                   |                    |                    |
|            | Shareholders of the company   | -                 | -                | -                 | -                 | -                  | (2.23)             |
|            | Non-controlling interest  | -                 | -                | -                 | -                 | -                  | (1.62)             |
|            |   | -                 | -                | -                 | -                 | -                  | (3.85)             |
| 21         | <b>Total Comprehensive Income for the period (13+18)</b>  | <b>(3,196.50)</b> | <b>919.00</b>    | <b>(2,928.69)</b> | <b>(4,079.07)</b> | <b>(38,147.14)</b> | <b>(44,517.14)</b> |



Continued

| Sl.<br>No. | Particulars  | Quarter Ended                             |                                   |   | Nine Months ended                          |   | Year Ended                                  |
|------------|--|---|-----------------------------------|---|--|---|---|
|            |  | Dec 31,<br>2021                           | Sep 30,<br>2021                   | Dec 31,<br>2020                           | Dec 31,<br>2021                            | Dec 31,<br>2020                             | Mar 31,<br>2021                             |
|            |  | (Unaudited)                               | (Unaudited)                       | (Unaudited)                               | (Unaudited)                                | (Unaudited)                                 | (Audited)                                   |
| 22         | <b>Total Comprehensive Income from Continuing operations (14+19)</b><br><b>Attributable to:</b><br>Shareholders of the company<br>Non-controlling interest   | (3,192.16)<br>(4.34)<br><b>(3,196.50)</b> | 924.29<br>(5.29)<br><b>919.00</b> | (2,943.84)<br>(4.11)<br><b>(2,947.95)</b> | (4,068.40)<br>(10.67)<br><b>(4,079.07)</b> | (38,477.58)<br>102.94<br><b>(38,374.64)</b> | (44,844.90)<br>104.11<br><b>(44,740.79)</b> |
| 23         | <b>Total Comprehensive Income from Discontinued operations (15+20)</b><br><b>Attributable to:</b><br>Shareholders of the company<br>Non-controlling interest   | -<br>-<br>-                               | -<br>-<br>-                       | 19.26<br>-<br>19.26                       | -<br>-<br>-                                | 140.04<br>87.46<br>227.50                   | 137.81<br>85.84<br>223.65                   |
| 24         | <b>Paid-up equity share capital (Face value ₹ 1/- each)</b>  | 1,462.25                                  | 1,462.25                          | 1,462.25                                  | 1,462.25                                   | 1,462.25                                    | 1,462.25                                    |
| 25         | <b>Earnings per share (of ₹ 1/- each not annualised)</b><br>(a) Basic<br>(i) Continuing operations<br>(ii) Discontinued operations<br><b>Total Operations</b><br>(b) Diluted<br>(i) Continuing operations<br>(ii) Discontinued operations<br><b>Total Operations</b> | (2.86)<br>-<br><b>(2.86)</b>              | (0.61)<br>-<br><b>(0.61)</b>      | (1.75)<br>0.01<br><b>(1.74)</b>           | (3.69)<br>-<br><b>(3.69)</b>               | (26.35)<br>0.10<br><b>(26.25)</b>           | (31.01)<br>0.10<br><b>(30.91)</b>           |

#### Segment Wise Revenue and Results

##### Primary Segment Information

| Particulars   | (₹ In Lakhs)      |                  |                   |                   |                    |                    |
|---|-------------------|------------------|-------------------|-------------------|--------------------|--------------------|
|   | Quarter Ended     |                  |                   | Nine Months ended |                    | Year Ended         |
|   | Dec 31,<br>2021   | Sep 30,<br>2021  | Dec 31,<br>2020   | Dec 31,<br>2021   | Dec 31,<br>2020    | Mar 31,<br>2021    |
| <b>A. Continuing Operations</b>   |                   |                  |                   |                   |                    |                    |
| <b>1. Segment Revenue</b>   |                   |                  |                   |                   |                    |                    |
| (i) Life Sciences   | 20,739.67         | 19,742.33        | 21,639.15         | 61,397.38         | 52,017.06          | 74,116.54          |
| (ii) Supply Chain Management  | -                 | -                | -                 | -                 | 3,284.91           | 3,284.91           |
| <b>Revenue from Operations</b>  | <b>20,739.67</b>  | <b>19,742.33</b> | <b>21,639.15</b>  | <b>61,397.38</b>  | <b>55,301.97</b>   | <b>77,401.45</b>   |
| <b>2. Segment Results</b>   |                   |                  |                   |                   |                    |                    |
| (i) Life Sciences   | (2,551.91)        | 464.46           | (744.30)          | (897.35)          | (17,567.35)        | (38,233.83)        |
| (ii) Supply Chain Management  | -                 | -                | -                 | -                 | 381.57             | 381.57             |
| <b>Total</b>  | <b>(2,551.91)</b> | <b>464.46</b>    | <b>(744.30)</b>   | <b>(897.35)</b>   | <b>(17,185.78)</b> | <b>(37,852.26)</b> |
| Less: (i) Finance cost  | 910.65            | 764.99           | 939.81            | 2,747.25          | 2,903.09           | 3,731.03           |
| (ii) Other Un-allocable Expenditure net off Un-allocable Income   | 611.60            | 420.96           | 594.07            | 1,402.25          | 17,625.15          | 2,296.30           |
| <b>Profit Before Tax - Continuing Operations</b>  | <b>(4,074.16)</b> | <b>(721.49)</b>  | <b>(2,278.18)</b> | <b>(5,046.85)</b> | <b>(37,714.02)</b> | <b>(43,879.59)</b> |
| <b>B. Discontinued Operations - Supply Chain Management</b>   |                   |                  |                   |                   |                    |                    |
| <b>Segment Revenue</b>  |                   |                  |                   |                   |                    |                    |
| <b>Segment Results</b>  |                   |                  |                   |                   |                    |                    |
| Less: (i) Finance cost  | -                 | -                | 19.26             | -                 | 317.46             | 317.46             |
| (ii) Other Un-allocable Expenditure net off Un-allocable Income   | -                 | -                | -                 | -                 | -                  | -                  |
| <b>Profit Before Tax - Discontinued Operations</b>  | <b>-</b>          | <b>-</b>         | <b>19.26</b>      | <b>-</b>          | <b>317.46</b>      | <b>317.46</b>      |
| 1 Segregation of assets, liabilities, depreciation and other non-cash expenses into various primary segments has not been carried out as the assets are used interchangeably between segments. Accordingly, no disclosure relating to segmental assets and liabilities has been made.   |                   |                  |                   |                   |                    |                    |
| 2 Consequent to disposal of a subsidiary viz. APA Engineering Pvt Ltd during the previous year, the group is operating in a single segment viz. Life Sciences. However, the group has continued to give the disclosures for Supply Chain Management segment for the previous quarters and year to the extent the same pertains to operations prior to the disposal of the subsidiary. |                   |                  |                   |                   |                    |                    |



Note :

- 1 The Consolidated Financial Results for the quarter and nine months ended December 31, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on February 08, 2022. The statutory auditors of the company have carried out Limited Review of the results for the quarter and nine months ended December 31, 2021.
- 2 The management has taken into consideration the impact of the known internal and external events arising from COVID-19 pandemic in the assessment of recoverability of trade receivables, goodwill on acquisition, intangible assets and contract assets up to the date of approval of these consolidated financial results. In this assessment, the group has performed sensitivity analysis on the key assumptions used. Such review and analysis performed by the group did not reveal any impairment losses. Since the impact assessment of COVID-19 is an ongoing process given the uncertainties associated with its nature and duration, the Group will continue to closely monitor any significant impact on the financial position. The impact of global health pandemic might be different from that estimated as at the date of approval of these financial results.
- 3 According to the intimations given by the parent company to the Stock Exchanges, the then proposed sale of investments in equity shares held in group companies to H.I.G. Taurus Pte. Ltd. and H.I.G. Taurus EAL Pte. Ltd. has been suspended in view of order from High Court of Madras. The Group had planned to repay the credit facilities in a subsidiary viz. TAKE Solutions Global Holdings Pte Ltd, Singapore (TAKE Ghpte) from the proceeds out of above referred suspended sale. Subsequently, lender banks have cancelled and recalled the credit facilities of ₹ 452 Crores (approx.) in TAKE Ghpte and have initiated disposal of equity share investments held in TAKE Ghpte by the parent company to recover their dues.



Based on the evaluation of the business situation, the management is confident that the group shall be able to sell the aforesaid investments in TAKE Ghpte and repay the credit facilities to the lender banks of TAKE Ghpte. As such, there is no indication of impairment in goodwill, intangible assets, etc. The management is also confident of recovery of trade/ unbilled receivables, other financial assets and other current assets of the Group in the normal course of business. The expenditure of ₹ 2,800 lakhs mainly in the nature of legal & professional fees pertaining to the aforesaid suspended sale of investments has been written off during the quarter ended December 31, 2021.

Accordingly, the net assets of TAKE Ghpte and its subsidiaries have been classified as investments held for sale under Ind AS 105, 'Non-Current Assets held for Sale and Discontinuing Operations,' from December 31, 2021. As stated above since no impairment indications exist, there would be no impact on the financial results for the quarter and nine months ended December 31, 2021.

- 4 The Code on Social Security, 2020 (the Code) has been enacted, which would impact contribution by the Group Companies registered in India towards applicable social security schemes. The Ministry of Labour and Employment has also released draft rules thereunder on November 13, 2020 and has invited suggestions from stakeholders which are under active consideration by the Ministry. The actual impact on account of this change will be evaluated and accounted for when notification becomes effective.
- 5 The Consolidated and Standalone financial results for the quarter ended December 31, 2021 are available on the Company's website ([www.takesolutions.com](http://www.takesolutions.com)) and the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com))
- 6 The financial results of TAKE Solutions Limited (Standalone information)

| Particulars                      | Quarter Ended   |                 |                 | Nine Months ended |                 | Year Ended      |
|----------------------------------|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|
|                                  | Dec 31,<br>2021 | Sep 30,<br>2021 | Dec 31,<br>2020 | Dec 31,<br>2021   | Dec 31,<br>2020 | Mar 31,<br>2021 |
|                                  | (Unaudited)     | (Unaudited)     | (Unaudited)     | (Unaudited)       | (Unaudited)     | (Audited)       |
| Total income                     | 1,233.76        | 420.00          | 253.06          | 2,346.17          | 1,152.47        | 1,221.72        |
| Net profit/(loss) before tax     | (48.62)         | 81.24           | 1,103.17        | 348.49            | 875.00          | 651.74          |
| Net profit/(loss) for the period | (50.09)         | 90.63           | 1,096.60        | 381.33            | 903.36          | 779.26          |
| Total comprehensive income       | (47.68)         | 93.04           | 1,099.73        | 387.29            | 913.10          | 783.55          |

- 7 Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

|   |   |   |   |
|---|---|---|---|
| Place : Chennai<br>Date : February 08, 2022 |  | For and on behalf of the Board of Directors<br><br>Srinivasan H.R.<br>Vice Chairman & Managing Director |  |
|---|---|---|---|